To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Read the latest news and updates on this trial.
March 08, 2021
Descartes-11 is part of Cartesian Therapeutics RNA ArmorySM, a cellular therapy platform that “enables mRNA-engineering any cell, to target to any tissue, any combination of therapies.” The platform utilizes autologous and allogeneic approaches to engineer products that optimize each therapy to different cell types. Moreover, the “army” of cells that is engineered deliver precision-targeted treatment directly to the myeloma cells with a defined half-life, which allows for repeat dosing and outpatient administration of some therapies.
The investigational Descartes-11 product is manufactured to express CAR molecules transiently rather than permanently, which could reduce some of the short- and long-term risks associated with traditional autologous CAR T-cell therapies.